Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/W mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BLyS production

Immunology. 2008 Oct;125(2):184-96. doi: 10.1111/j.1365-2567.2008.02835.x. Epub 2008 Apr 7.

Abstract

The role of natural killer (NK) T cells in the development of lupus-like disease in mice is still controversial. We treated NZB/W mice with anti-NK1.1 monoclonal antibodies (mAbs) and our results revealed that administration of either an irrelevant immunoglobulin G2a (IgG2a) mAb or an IgG2a anti-NK1.1 mAb increased the production of anti-dsDNA antibodies in young NZB/W mice. However, the continuous administration of an anti-NK1.1 mAb protected aged NZB/W mice from glomerular injury, leading to prolonged survival and stabilization of the proteinuria. Conversely, the administration of the control IgG2a mAb led to an aggravation of the lupus-like disease. Augmented titres of anti-dsDNA in NZB/W mice, upon IgG2a administration, correlated with the production of BAFF/BLyS by dendritic, B and T cells. Treatment with an anti-NK1.1 mAb reduced the levels of interleukin-16, produced by T cells, in spleen cell culture supernatants from aged NZB/W. Adoptive transfer of NK T cells from aged to young NZB/W accelerated the production of anti-dsDNA in recipient NZB/W mice, suggesting that NK T cells from aged NZB/W are endowed with a B-cell helper activity. In vitro studies, using purified NK T cells from aged NZB/W, showed that these cells provided helper B-cell activity for the production of anti-dsDNA. We concluded that NK T cells are involved in the progression of lupus-like disease in mature NZB/W mice and that immunoglobulin of the IgG2a isotype has an enhancing effect on antibody synthesis due to the induction of BAFF/BLyS, and therefore have a deleterious effect in the NZB/W mouse physiology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / immunology
  • Animals
  • Antibodies, Antinuclear / biosynthesis
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, Ly / immunology
  • B-Cell Activating Factor / biosynthesis*
  • Cells, Cultured
  • Disease Progression
  • Female
  • Immunoglobulin G / immunology
  • Immunoglobulin G / therapeutic use*
  • Interleukin-16 / biosynthesis
  • Killer Cells, Natural / immunology
  • Killer Cells, Natural / transplantation
  • Lipopolysaccharides / immunology
  • Liver / immunology
  • Lupus Nephritis / immunology
  • Lupus Nephritis / prevention & control*
  • Mice
  • Mice, Inbred Strains
  • NK Cell Lectin-Like Receptor Subfamily B / immunology
  • Severity of Illness Index
  • Spleen / immunology
  • T-Lymphocytes, Helper-Inducer / immunology

Substances

  • Antibodies, Antinuclear
  • Antibodies, Monoclonal
  • Antigens, Ly
  • B-Cell Activating Factor
  • Immunoglobulin G
  • Interleukin-16
  • Klrb1c protein, mouse
  • Lipopolysaccharides
  • NK Cell Lectin-Like Receptor Subfamily B
  • Tnfsf13b protein, mouse